PFE vs VRT: Which Is the Better Buy?

Side-by-side comparison of Pfizer Inc. and Vertiv Holdings Co — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-18.
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
VS
Vertiv Holdings Co · Industrials
$307.34
-11.3% upside to fair value
Grade D High Quality
QuantHub Verdict
PFE has more upside to fair value (+30.1%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric PFE VRT
Current Price $26.91 $307.34
Fair Value Estimate $35.00 $272.65
Upside to Fair Value +30.1% -11.3%
Market Cap $153.0B $117.6B
Forward P/E 9.5x 88.2x
EV / EBITDA 13.8x 55.3x
Price / Sales 2.4x 11.5x
Price / FCF 16.8x 61.2x
Revenue Growth YoY -1.6% +7.6%
Gross Margin 70.3% 34.8%
Operating Margin 24.7% 18.2%
Return on Equity 9.0% 40.3%
Dividend Yield 6.4% 0%
FCF Yield 5.9% 1.63%
Analyst Consensus Hold Strong Buy
Investment Thesis
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
VRT — Vertiv Holdings Co
Vertiv Holdings Co operates as a global leader in digital critical infrastructure, providing technology products and solutions primarily for data centers, telecom, and AI-driven markets. The company demonstrates strong business quality with 40.3% return on equity, 7.6% revenue growth, and 11.8% earnings growth year-over-year, supported by a robust $1.89 billion free cash flow and a $15 billion ba…
Accumulation Zones
Metric PFE VRT
Zone Low $25.00 $204.49
Zone High $29.00 $231.75
In Buy Zone? Yes No
← PFE Research    VRT Research →    All Research